
Insulet Corporation PODD
$ 202.08
2.16%
Quarterly report 2025-Q3
added 04-04-2026
Insulet Corporation Accounts Receivables 2011-2026 | PODD
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Insulet Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 161 M | 83.8 M | 69.3 M | 63.3 M | 53.4 M | 28.8 M | 42.5 M | 39.9 M | 33.1 M | 33.3 M | 23.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 161 M | 23.2 M | 57.4 M |
Quarterly Accounts Receivables Insulet Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154 M | 135 M | 114 M | 100 M | 97.9 M | 95.3 M | 83.8 M | 83.8 M | 83.8 M | 69.3 M | 69.3 M | 69.3 M | 69.3 M | 63.3 M | 63.3 M | 63.3 M | 63.3 M | 53.4 M | 53.4 M | 53.4 M | 53.4 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 35.2 M | 39.9 M | 39.9 M | 39.9 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | 23.2 M | 55.3 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
996 M | $ 186.6 | 3.28 % | $ 14 B | ||
|
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | ||
|
AxoGen
AXGN
|
26.2 M | $ 34.49 | 3.05 % | $ 1.59 B | ||
|
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | ||
|
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
371 M | $ 12.72 | 3.25 % | $ 1.72 B | ||
|
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | ||
|
Bio-Rad Laboratories
BIO
|
452 M | $ 292.85 | 1.62 % | $ 8.26 B | ||
|
Cytosorbents Corporation
CTSO
|
7.55 M | $ 0.58 | -0.87 % | $ 36.1 M | ||
|
EDAP TMS S.A.
EDAP
|
18.6 M | $ 3.19 | -4.21 % | $ 119 M | ||
|
Bruker Corporation
BRKR
|
566 M | $ 40.45 | 3.57 % | $ 6.03 K | ||
|
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
6.55 M | $ 10.37 | 3.6 % | $ 294 M | ||
|
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | ||
|
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | ||
|
Electromed
ELMD
|
24.7 M | $ 25.33 | 1.52 % | $ 214 M | ||
|
IRIDEX Corporation
IRIX
|
7.61 M | $ 1.03 | 0.01 % | $ 17.4 M | ||
|
Myomo
MYO
|
4.1 M | $ 0.76 | 3.85 % | $ 31.8 M | ||
|
Inogen
INGN
|
38.9 M | $ 6.45 | - | $ 172 M | ||
|
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
679 M | $ 95.85 | 3.09 % | $ 13 B | ||
|
Helius Medical Technologies
HSDT
|
117 K | $ 1.99 | -1.97 % | $ 1.21 M | ||
|
Butterfly Network
BFLY
|
20.8 M | $ 4.43 | 3.62 % | $ 938 M | ||
|
LENSAR
LNSR
|
6.38 M | $ 6.11 | 3.21 % | $ 73.1 M | ||
|
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | ||
|
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 17.8 | 5.01 % | $ 418 M | ||
|
Delcath Systems
DCTH
|
11.7 M | $ 10.78 | 3.16 % | $ 386 M | ||
|
Inspire Medical Systems
INSP
|
120 M | $ 56.23 | 2.46 % | $ 1.65 B | ||
|
CONMED Corporation
CNMD
|
248 M | $ 39.57 | 2.89 % | $ 1.23 B | ||
|
LivaNova PLC
LIVN
|
216 M | $ 65.44 | 1.33 % | $ 3.57 B | ||
|
Integer Holdings Corporation
ITGR
|
346 M | $ 89.11 | 1.57 % | $ 3.1 B | ||
|
Invacare Corporation
IVC
|
88 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
660 M | $ 78.24 | 0.15 % | $ 45.8 B |